Differences in the population structure of Neisseria meningitidis in two Australian states: Victoria and Western Australia

Shakeel Mowlaboccus, Christopher A. Mullally, Peter C. Richmond, Benjamin P. Howden, Kerrie Stevens, David J. Speers, Anthony D. Keil, Ottar N. Bjørnstad, Timothy T. Perkins, Charlene M. Kahler

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Neisseria meningitidis is the causative agent of invasive meningococcal disease (IMD). A recombinant vaccine called Bexsero® incorporates four subcapsular antigens (fHbp, NHBA, NadA and PorA) which are used to assign a Bexsero® antigen sequence type (BAST) to each meningococcal strain. The vaccine elicits an immune response against combinations of variants of these antigens which have been grouped into specific BAST profiles that have been shown to have different distributions within geographical locations thus potentially affecting the efficacy of the vaccine. In this study, invasive meningococcal disease isolates from the western seaboard of Australia (Western Australia; WA) were compared to those from the south-eastern seaboard (Victoria; VIC) from 2008 to 2012. Whole-genome sequencing (WGS) of 131 meningococci from VIC and 70 meningococci from WA were analysed for MLST, FetA and BAST profiling. Serogroup B predominated in both jurisdictions and a total of 10 MLST clonal complexes (cc) were shared by both states. Isolates belonging to cc22, cc103 and cc1157 were unique to VIC whilst isolates from cc60 and cc212 were unique to WA. Clonal complex 41/44 represented one-third of the meningococcal population in each state but the predominant ST was locally different: ST-6058 in VIC and ST-146 in WA. Of the 108 BAST profiles identified in this collection, only 9 BASTs were simultaneously observed in both states. A significantly larger proportion of isolates in VIC harboured alleles for the NHBA-2 peptide and fHbp-1, antigenic variants predicted to be covered by the Bexsero® vaccine. The estimate for vaccine coverage in WA (47.1% [95% CI: 41.1–53.1%]) was significantly lower than that in VIC (66.4% [95% CI: 62.3–70.5%]). In conclusion, the antigenic structure of meningococci causing invasive disease in two geographically distinct states of Australia differed significantly during the study period which may affect vaccine effectiveness and highlights the need for representative surveillance when predicting potential impact of meningococcal B vaccines.

Original languageEnglish (US)
Article numbere0186839
JournalPloS one
Volume12
Issue number10
DOIs
StatePublished - Oct 2017

Fingerprint

Victoria (Australia)
Neisseria meningitidis
Western Australia
Victoria
population structure
Vaccines
vaccines
antigens
Antigens
Population
Meningococcal Vaccines
Geographical distribution
Synthetic Vaccines
Geographical Locations
recombinant vaccines
4CMenB vaccine
serotypes
Genes
Alleles
immune response

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Mowlaboccus, S., Mullally, C. A., Richmond, P. C., Howden, B. P., Stevens, K., Speers, D. J., ... Kahler, C. M. (2017). Differences in the population structure of Neisseria meningitidis in two Australian states: Victoria and Western Australia. PloS one, 12(10), [e0186839]. https://doi.org/10.1371/journal.pone.0186839
Mowlaboccus, Shakeel ; Mullally, Christopher A. ; Richmond, Peter C. ; Howden, Benjamin P. ; Stevens, Kerrie ; Speers, David J. ; Keil, Anthony D. ; Bjørnstad, Ottar N. ; Perkins, Timothy T. ; Kahler, Charlene M. / Differences in the population structure of Neisseria meningitidis in two Australian states : Victoria and Western Australia. In: PloS one. 2017 ; Vol. 12, No. 10.
@article{b47a0271479749cf8a1a643f58734010,
title = "Differences in the population structure of Neisseria meningitidis in two Australian states: Victoria and Western Australia",
abstract = "Neisseria meningitidis is the causative agent of invasive meningococcal disease (IMD). A recombinant vaccine called Bexsero{\circledR} incorporates four subcapsular antigens (fHbp, NHBA, NadA and PorA) which are used to assign a Bexsero{\circledR} antigen sequence type (BAST) to each meningococcal strain. The vaccine elicits an immune response against combinations of variants of these antigens which have been grouped into specific BAST profiles that have been shown to have different distributions within geographical locations thus potentially affecting the efficacy of the vaccine. In this study, invasive meningococcal disease isolates from the western seaboard of Australia (Western Australia; WA) were compared to those from the south-eastern seaboard (Victoria; VIC) from 2008 to 2012. Whole-genome sequencing (WGS) of 131 meningococci from VIC and 70 meningococci from WA were analysed for MLST, FetA and BAST profiling. Serogroup B predominated in both jurisdictions and a total of 10 MLST clonal complexes (cc) were shared by both states. Isolates belonging to cc22, cc103 and cc1157 were unique to VIC whilst isolates from cc60 and cc212 were unique to WA. Clonal complex 41/44 represented one-third of the meningococcal population in each state but the predominant ST was locally different: ST-6058 in VIC and ST-146 in WA. Of the 108 BAST profiles identified in this collection, only 9 BASTs were simultaneously observed in both states. A significantly larger proportion of isolates in VIC harboured alleles for the NHBA-2 peptide and fHbp-1, antigenic variants predicted to be covered by the Bexsero{\circledR} vaccine. The estimate for vaccine coverage in WA (47.1{\%} [95{\%} CI: 41.1–53.1{\%}]) was significantly lower than that in VIC (66.4{\%} [95{\%} CI: 62.3–70.5{\%}]). In conclusion, the antigenic structure of meningococci causing invasive disease in two geographically distinct states of Australia differed significantly during the study period which may affect vaccine effectiveness and highlights the need for representative surveillance when predicting potential impact of meningococcal B vaccines.",
author = "Shakeel Mowlaboccus and Mullally, {Christopher A.} and Richmond, {Peter C.} and Howden, {Benjamin P.} and Kerrie Stevens and Speers, {David J.} and Keil, {Anthony D.} and Bj{\o}rnstad, {Ottar N.} and Perkins, {Timothy T.} and Kahler, {Charlene M.}",
year = "2017",
month = "10",
doi = "10.1371/journal.pone.0186839",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

Mowlaboccus, S, Mullally, CA, Richmond, PC, Howden, BP, Stevens, K, Speers, DJ, Keil, AD, Bjørnstad, ON, Perkins, TT & Kahler, CM 2017, 'Differences in the population structure of Neisseria meningitidis in two Australian states: Victoria and Western Australia', PloS one, vol. 12, no. 10, e0186839. https://doi.org/10.1371/journal.pone.0186839

Differences in the population structure of Neisseria meningitidis in two Australian states : Victoria and Western Australia. / Mowlaboccus, Shakeel; Mullally, Christopher A.; Richmond, Peter C.; Howden, Benjamin P.; Stevens, Kerrie; Speers, David J.; Keil, Anthony D.; Bjørnstad, Ottar N.; Perkins, Timothy T.; Kahler, Charlene M.

In: PloS one, Vol. 12, No. 10, e0186839, 10.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differences in the population structure of Neisseria meningitidis in two Australian states

T2 - Victoria and Western Australia

AU - Mowlaboccus, Shakeel

AU - Mullally, Christopher A.

AU - Richmond, Peter C.

AU - Howden, Benjamin P.

AU - Stevens, Kerrie

AU - Speers, David J.

AU - Keil, Anthony D.

AU - Bjørnstad, Ottar N.

AU - Perkins, Timothy T.

AU - Kahler, Charlene M.

PY - 2017/10

Y1 - 2017/10

N2 - Neisseria meningitidis is the causative agent of invasive meningococcal disease (IMD). A recombinant vaccine called Bexsero® incorporates four subcapsular antigens (fHbp, NHBA, NadA and PorA) which are used to assign a Bexsero® antigen sequence type (BAST) to each meningococcal strain. The vaccine elicits an immune response against combinations of variants of these antigens which have been grouped into specific BAST profiles that have been shown to have different distributions within geographical locations thus potentially affecting the efficacy of the vaccine. In this study, invasive meningococcal disease isolates from the western seaboard of Australia (Western Australia; WA) were compared to those from the south-eastern seaboard (Victoria; VIC) from 2008 to 2012. Whole-genome sequencing (WGS) of 131 meningococci from VIC and 70 meningococci from WA were analysed for MLST, FetA and BAST profiling. Serogroup B predominated in both jurisdictions and a total of 10 MLST clonal complexes (cc) were shared by both states. Isolates belonging to cc22, cc103 and cc1157 were unique to VIC whilst isolates from cc60 and cc212 were unique to WA. Clonal complex 41/44 represented one-third of the meningococcal population in each state but the predominant ST was locally different: ST-6058 in VIC and ST-146 in WA. Of the 108 BAST profiles identified in this collection, only 9 BASTs were simultaneously observed in both states. A significantly larger proportion of isolates in VIC harboured alleles for the NHBA-2 peptide and fHbp-1, antigenic variants predicted to be covered by the Bexsero® vaccine. The estimate for vaccine coverage in WA (47.1% [95% CI: 41.1–53.1%]) was significantly lower than that in VIC (66.4% [95% CI: 62.3–70.5%]). In conclusion, the antigenic structure of meningococci causing invasive disease in two geographically distinct states of Australia differed significantly during the study period which may affect vaccine effectiveness and highlights the need for representative surveillance when predicting potential impact of meningococcal B vaccines.

AB - Neisseria meningitidis is the causative agent of invasive meningococcal disease (IMD). A recombinant vaccine called Bexsero® incorporates four subcapsular antigens (fHbp, NHBA, NadA and PorA) which are used to assign a Bexsero® antigen sequence type (BAST) to each meningococcal strain. The vaccine elicits an immune response against combinations of variants of these antigens which have been grouped into specific BAST profiles that have been shown to have different distributions within geographical locations thus potentially affecting the efficacy of the vaccine. In this study, invasive meningococcal disease isolates from the western seaboard of Australia (Western Australia; WA) were compared to those from the south-eastern seaboard (Victoria; VIC) from 2008 to 2012. Whole-genome sequencing (WGS) of 131 meningococci from VIC and 70 meningococci from WA were analysed for MLST, FetA and BAST profiling. Serogroup B predominated in both jurisdictions and a total of 10 MLST clonal complexes (cc) were shared by both states. Isolates belonging to cc22, cc103 and cc1157 were unique to VIC whilst isolates from cc60 and cc212 were unique to WA. Clonal complex 41/44 represented one-third of the meningococcal population in each state but the predominant ST was locally different: ST-6058 in VIC and ST-146 in WA. Of the 108 BAST profiles identified in this collection, only 9 BASTs were simultaneously observed in both states. A significantly larger proportion of isolates in VIC harboured alleles for the NHBA-2 peptide and fHbp-1, antigenic variants predicted to be covered by the Bexsero® vaccine. The estimate for vaccine coverage in WA (47.1% [95% CI: 41.1–53.1%]) was significantly lower than that in VIC (66.4% [95% CI: 62.3–70.5%]). In conclusion, the antigenic structure of meningococci causing invasive disease in two geographically distinct states of Australia differed significantly during the study period which may affect vaccine effectiveness and highlights the need for representative surveillance when predicting potential impact of meningococcal B vaccines.

UR - http://www.scopus.com/inward/record.url?scp=85032001553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032001553&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0186839

DO - 10.1371/journal.pone.0186839

M3 - Article

C2 - 29065137

AN - SCOPUS:85032001553

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0186839

ER -